Published 4 months ago

ESMO 2024: Dr. Jonasch on implications of positive HIF-2α inhibitor data in ccRCC

Summary by urologytime.com

"It clearly shows that blocking HIF-2α is a meaningful way of interacting with disease biology in clear cell renal cell carcinoma," says Eric Jonasch, MD.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated4 months agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

ESMO 2024: Dr. Jonasch on implications of positive HIF-2α inhibitor data in ccRCC

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics